Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 5, 2000, Pages 357-364

  Sengeløv, Lisa ^a   Kamby, Claus ^b   Geertsen, Poul ^b   Andersen, Lisbeth Juhler ^c   Von Der Maase, Hans ^c  

^a FINSEN LABORATORY   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bladder cancer; Chemotherapy; Predictive factors; Response

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FOLINIC ACID; HEMOGLOBIN; METHOTREXATE; MITOXANTRONE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0033747013     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000176     Document Type: Article

References (37)

1. Advanced bladder cancer: The need to identify new agents in the post M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world
2. Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy
3. Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer
4. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer
5. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder
6. DNA ploidy and P-glycoprotein expression as predictive factors of response to neoadjuvant chemotherapy for invasive bladder cancer
7. The utility of tumor markers in assessing the response to chemotherapy in advanced bladder cancer
8. Chemotherapy for urothelial tract malignancies: Breaking the deadlock
9. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: Ten-year outcome
10. Genitourinary group phase II study of chemotherapy in stage T3-4 N0-X M0 transitional cell cancer of the bladder: Prognostic factor analysis
11. A phase II study of cisplatin plus methotrexate with folinic acid rescue in metastatic or locally recurrent transitional cell carcinoma of the urothelium
12. Platinum analogue combination chemotherapy: Cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors
13. Cisplatin, methotrexate and mitoxantrone in patients with metastatic or advanced urothelial cancer
14. Docetaxel (taxotere) and cisplatin in metastatic urothelial cancer: A phase II study
15. Assessment of patients with metastatic transitional cell carcinoma of the urinary tract
16. Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years
17. Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma
18. Analysis of survival by tumor response
19. Nonparametric estimation from incomplete observations
20. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: Results and a report on prognostic factors in a medical research council study. MRC Advanced Bladder Cancer Working Party
21. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma
22. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract
23. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse
24. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors
25. Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California oncology group study
26. The risk of determining risk with multivariate models
27. Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology Group
28. Factors affecting the outcome of patients with advanced urothelial cancer following chemotherapy with methotrexate, vinblastine, adriamycin, and cisplatin
29. M-VAC or MVC for the treatment of advanced transitional cell carcinoma: Metastatic, induction, and adjuvant
30. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
31. Blood flow and oxygenation status of human tumors. Clinical investigations
32. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion
33. Nonbladder primary site of transitional cell carcinoma (TCC) does not affect probability of response to MVAC or survival
34. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy
35. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy
36. M-VAC in transitional cell carcinoma (TCC): Prognostic factors and long time survival in 203 patients